Siatis Perry C 4
4 · AbbVie Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
AbbVie (ABBV) EVP Perry C. Siatis Receives Performance Awards
What Happened Perry C. Siatis, Executive Vice President, General Counsel and Secretary of AbbVie Inc., was granted/received performance-based equity on February 18, 2026. The filing reports 33,518 shares of AbbVie common stock issued under performance awards (granted in prior years) and a derivative award option covering 19,500 shares. All reported acquisitions show a $0 price (awards/options); the total count across awards and the option is 53,018 underlying shares, with the performance shares to be issued on February 28, 2026.
Key Details
- Transaction date: February 18, 2026; Form 4 filed February 20, 2026 (appears timely).
- Reported items:
- 16,290 shares (performance share award; footnote F1)
- 5,792 shares (performance-vesting RSU; F2)
- 5,628 shares (performance-vesting RSU; F3)
- 5,808 shares (performance-vesting RSU; F4)
- 19,500-share employee stock option (derivative; F5)
- Price: $0.00 for all reported acquisitions (awards/options).
- Shares owned after the transactions: not disclosed in the provided filing.
- Notable footnotes:
- F1–F4: These are performance-based awards granted in 2023–2025 whose vesting restrictions were certified as met; shares will be issued on Feb 28, 2026.
- F5: Employee stock option granted under AbbVie’s 2013 Incentive Stock Program; becomes exercisable in annual increments of 6,500 on Feb 18 of 2027, 2028 and 2029. Transaction exempt from Section 16 under Rule 16b-3.
Context These entries are awards and an option grant/release of performance restrictions, not open-market purchases or sales. Performance awards are typically part of executive compensation and reflect previously granted awards having met performance criteria; they do not necessarily signal the insider buying or selling stock. The option is a standard grant with staged exercisability over 2027–2029.
Insider Transaction Report
- Award
Common Stock, $0.01 par value
[F1]2026-02-18+16,290→ 20,909 total - Award
Common Stock, $0.01 par value
[F2]2026-02-18+5,792→ 26,701 total - Award
Common Stock, $0.01 par value
[F3]2026-02-18+5,628→ 32,329 total - Award
Common Stock, $0.01 par value
[F4]2026-02-18+5,808→ 38,137 total - Award
Option (Right to buy)
[F5]2026-02-18+19,500→ 19,500 totalExercise: $230.04Exp: 2036-02-17→ Common Stock (19,500 underlying)
Footnotes (5)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,500 on February 18, 2027, 6,500 on February 18, 2028, and 6,500 on February 18, 2029.